PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 3, 2026Value in Health0 citationsOpen Access

Economic Impact of Respiratory Syncytial Virus Prefusion F Protein-Based Vaccination and Nirsevimab Prophylaxis on Respiratory-Syncytial-Virus-Associated Disease Among Japanese Infants

View Full Paper
SHShu-Ling HoshiXSXerxes SeposoMKMasahide Kondo

Key Points

  • The seasonal RSV preF vaccination strategy is identified as cost-effective, indicating a favorable economic outcome for healthcare systems.
  • Analysis suggests a threshold of JPY 5,000,000 or US$33,333 per quality-adjusted life year (QALY) as the benchmark for cost-effectiveness evaluation.

Structured PICO

Is Respiratory Syncytial Virus Prefusion F Protein-Based Vaccination or Nirsevimab Prophylaxis cost-effective for preventing RSV-associated disease in Japanese infants?

P
Population
Japanese infants
I
Intervention
Respiratory Syncytial Virus Prefusion F Protein-Based Vaccination (RSVpreF) and Nirsevimab Prophylaxis
O
Outcome
Cost-effectiveness (Quality-Adjusted Life Years / QALY)

Seasonal RSVpreF vaccination is a cost-effective strategy for preventing RSV-associated disease in Japanese infants at a threshold of US$33,333 per QALY.

Abstract

Only seasonal RSVpreF strategy is cost-effective under the JPY5 000 000/US33 333 per QALY willingness-to-pay threshold.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Hoshi et al. (2026) studied this question.

synapsesocial.com/papers/69a76663badf0bb9e87dcd07https://doi.org/10.1016/j.jval.2026.01.010
Ask AI
Helpful
Bookmark
Share
View Full Paper